🔗 Share this article

Given that America proceeds with historic revisions to its vaccine recommendations, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on Covid shots in the global health crisis and has concentrated on possible fatalities after Covid immunization in her brief time at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Health officials were set to reveal major changes to the childhood vaccine schedule in December, synchronizing the US with Denmark’s national calendar, sources say – a major change that would put the US at odds with a large portion of the world with no evidence for public health gain. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s CDER, the fifth individual to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood shot schedules in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Background

Dr. Høeg has no apparent background in pharmaceutical research, oversight or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “understand legal statutes and the research of medication creation”, said Janet Woodcock. “Objectively, she lacks the type of experience that previous people who headed CBER have had.”

This division has an immense range of responsibilities at the FDA, she stated.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and all of those have to be looked after,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant management component to the role, which supervises over 5,000 staff members. “It is a massive administrative position, if you do it right,” Woodcock added.

Response and Contentious Initiatives

When asked about inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among agency officials on vaccines, a press secretary responded that the “inquiries stem from flawed presumptions”.

“This background aligns with the functions of her job,” the representative explained, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a contentious expedited drug-approval program that allegedly worried her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who takes the decisions?” Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, except for immunizations.”

Established History on Immunizations

With immunizations, Høeg has a clearer, if problematic, history, Howard said. She released a research paper using non-validated volunteer-provided data to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Part of her “wish list” for the current administration included revising rules for new vaccines and ending “non-essential” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources proposed barring adolescent males from getting Covid vaccinations.

“She is an all-around true believer who starts off with her conclusions and reverse-engineers to accommodate the science in a highly disingenuous, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of other skeptics, {like|